Page last updated: 2024-08-25

rosiglitazone and Corneal Wavefront Aberration

rosiglitazone has been researched along with Corneal Wavefront Aberration in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bühren, J; Ciufo, D; DeMagistris, M; Hindman, HB; Huxlin, KR; Jeon, KI; MacRae, S; Phipps, RP; Sime, PJ	1

Other Studies

1 other study(ies) available for rosiglitazone and Corneal Wavefront Aberration

Article	Year
Topical rosiglitazone is an effective anti-scarring agent in the cornea. PloS one, 2013, Volume: 8, Issue:8 Topics: Actins; Administration, Topical; Animals; Cats; Cell Differentiation; Cells, Cultured; Cicatrix; Cornea; Corneal Wavefront Aberration; Drug Evaluation, Preclinical; Myofibroblasts; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta; Treatment Outcome; Wound Healing	2013

Article

Year

Topical rosiglitazone is an effective anti-scarring agent in the cornea.

PloS one, 2013, Volume: 8, Issue:8

Topics: Actins; Administration, Topical; Animals; Cats; Cell Differentiation; Cells, Cultured; Cicatrix; Cornea; Corneal Wavefront Aberration; Drug Evaluation, Preclinical; Myofibroblasts; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta; Treatment Outcome; Wound Healing

2013